PHA Pharmagest Interactive SA

EQUASENS (ex Pharmagest Interactive) joins Euronext’s new TECH LEADERS segment

EQUASENS (ex Pharmagest Interactive) joins Euronext’s new TECH LEADERS segment

                                            Villers-lès-Nancy, 27 June 2022 - 7:00 a.m. (CET)

PRESS RELEASE

EQUASENS (formerly PHARMAGEST INTERACTIVE)



joins Euronext’s new TECH LEADERS segment

(Euronext Paris™ - Compartment A - ISIN: FR0012882389) is proud to be included in the new market segment of Euronext Paris: the Euronext Tech Leaders, a selection of

100+ high-growth European technology companies.

The new Tech Leaders were selected from an ecosystem of 700 technology companies listed on Euronext markets, based on their technological leadership, market capitalisation and growth profile.

Thierry CHAPUSOT, Chairman of the Board of Directors of Equasens Group, commenting on this development stated: “We are very proud to have been selected by Euronext to join this new segment. Equasens Group, and all its teams, are driven by a culture of innovation where technology is used as a tool to promote the health and well-being of a maximum number of people. Our presence in this new segment is a testimony to our efforts, our patient-centred strategy and the efficiency of our business model. This will increase our visibility among international investors in the technology sector and allow us to benefit from the specific mechanisms offered by Euronext when the next index for this new segment is created. It is also excellent news for the liquidity of our shares.”

About

With more than 1,200 employees fulfilling a vital role as “Citizens in the Service of Health and Well-Being”, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.

With operations in France, Italy, Belgium, Luxembourg and the United Kingdom, Equasens Group is currently developing the leading healthcare platform and a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment A

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable by inclusion

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).

ISIN: FR0012882389 - Ticker Code: EQS

For all the latest news on Equasens Group go to

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Jean-Yves SAMSON

Tel. +33 (0)3 83 15 90 67 -

Media Relations:

FIN’EXTENSO - Isabelle APRILE

+33 (0)1 39 97 61 22 -   

Attachment



EN
27/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE

Equasens: availability of AGM preparatory materials

Equasens: availability of AGM preparatory materials Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING MATERIALS WEBCAST LIVE EQUASENS hereby provides notice to shareholders of the Annual Ordinary General Meeting to be held on Wednesday, June 25, 2025 at 5.30 pm at the Company’s registered office located in Villers-lès-Nancy (Technopôle de Nancy-Brabois - 5 Allée de Saint Cloud). The original French language version of the agenda and the resolutions submitted by the Board of Directors to the Or...

 PRESS RELEASE

EQUASENS : modalités de mise à disposition des documents préparatoires...

EQUASENS : modalités de mise à disposition des documents préparatoires à l'AG Villers-lès-Nancy, le 6 juin 2025 – 18:00 (CET) COMMUNIQUE DE PRESSE ASSEMBLEE GENERALE ORDINAIRE ANNUELLE AVIS DE CONVOCATION MISE EN LIGNE DES DOCUMENTS PREPARATOIRES RETRANSMISSION EN DIRECT La société EQUASENS invite ses actionnaires à participer à l’Assemblée Générale Ordinaire Annuelle qui se réunira le mercredi 25 juin 2025, à 17 heures 30, au Siège Social à Villers-lès-Nancy (Technopôle de Nancy-Brabois - 5 Allée de Saint Cloud). L'avis de réunion préalable, comprenant notamment l'ordre du jour de...

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - CA T1 - La reprise prend forme / Achat - Obj. 71,9 € ...

CA T1 de 57 M€ +6,9% (+5,9% à périmètre constant) / 56,5 M€ attendus ; Apport de Calimed 0,5 M€.

 PRESS RELEASE

Equasens: Q1 revenue at 31 March 2025

Equasens: Q1 revenue at 31 March 2025 Villers-lès-Nancy, 12 May 2025 - 6:00 PM (CET) PRESS RELEASE Q1 revenue at 31 March 2025: €57.0m+ 6.9% growth on a reported basis and + 5.9% like-for-like Q1 2025 REVENUE (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Equasens Group 53.357.03.76.9%0.53.25.9%Q1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Pharmagest39.842.02.25.5% 2.25.5%Axigate Link7.88.30.45.5% 0.45.5%e-Connec...

 PRESS RELEASE

EQUASENS : Chiffre d’affaires au 31 mars 2025

EQUASENS : Chiffre d’affaires au 31 mars 2025 Villers-lès-Nancy, le 12 mai 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 31 mars 2025 à 57,0 M€+ 6,9% en croissance publiée et + 5,9% en croissance organique CA T1 2025 (M€)Publié 2024Publié 2025Variation/publiéDont Croissances externesVariation/périmètre comparable (croissance organique)Groupe Equasens 53,357,03,76,9%0,53,25,9%CA T1 2025 / Division (M€)Publié 2024Publié 2025Variation/publiéDont Croissances externesVariation/périmètre comparable (croissance organique)Pharmagest39,842,02,25,5% 2,25,5%Axigate Link7,88,30,45,5%...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch